2014 Newsroom

Keyword Search
 
2014 | 2013 | 2012
DateTitle 
04/16/14Intrexon Appoints Former Ernst & Young CEO James S. Turley to Board of Directors
GERMANTOWN, Md., April 16, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of James S. Turley to its Board of Directors, effective April 16. Mr. Turley will occupy the board seat vacated by Thomas Reed, Ph.D., Founder and Chief Science Officer of Intrexon.  Dr. Reed will continue to serve as Chief Science Officer. Mr. Turley is the former Chairman and Chief Executive Officer of Ernst & Young.  He led the firm from 200... 
Printer Friendly Version
03/31/14Intrexon Announces Annual Report and Fourth Quarter Financial Results
GERMANTOWN, Md., March 31, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its 2013 annual and fourth quarter results for 2013.  Annual Highlights Highlights for 2013 included: Completion of Intrexon's initial public offering which, after taking into effect the exercise of the underwriters' over-allotment option, resulted in net proceeds to the company of approximately $168.3 million; the initial public offering closed less than... 
Printer Friendly Version
03/27/14Intrexon Forms Energy Collaboration for Gas-to-Liquids Bioconversion
Joint Venture to Generate High-Value Oil Products from Low-Cost Natural Gas SAN CARLOS, Calif., March 27, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the formation of Intrexon Energy Partners (IEP), a joint venture with a select group of external investors, to optimize and scale-up Intrexon's gas-to-liquid (GTL) bioconversion platform for the production of fuels and lubricants.  IEP's first target product is isobutanol for gasolin... 
Printer Friendly Version
03/17/14Intrexon Names Dr. Samuel Broder as Executive Vice President of Scientific and Public Affairs
GERMANTOWN, Md., March 17, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that Samuel Broder, M.D., most recently Chairman of Intrexon's Health Sector and former Director of the National Cancer Institute, has been named as Executive Vice President of Scientific and Public Affairs reporting to Chairman and Chief Executive Officer Randal J. Kirk.  In the new role, Dr. Broder will lead Intrexon's communications programs with media, academ... 
Printer Friendly Version
03/13/14Intrexon Acquires Laboratory Operations from Codexis and Expands Presence to Europe
Company Increases Bioproduction Capabilities and Capacity SAN CARLOS, Calif., March 13, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex chemistry industries. The acquisition will expand Intrexon's strain and protein development capabilities, as well as strengthen fermenta... 
Printer Friendly Version
03/12/14Intrexon Appoints Dr. Kelly Huang as Head of Newly Established Consumer Sector
Former Endo Health and Johnson & Johnson Executive to Join as Senior Vice President GERMANTOWN, Md., March 12, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Kelly Huang, Ph.D., most recently President of HealthTronics, Inc., a subsidiary of Endo Health Solutions, to head the Company's newly established Consumer Sector. Dr. Huang will join Intrexon effective March 17, reporting to Chairman and Chief Executive Offi... 
Printer Friendly Version
03/11/14Intrexon to Present at the 2014 Barclays Global Healthcare Conference
GERMANTOWN, Md., March 11, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that Krish Krishnan, Chief Operating Officer of Intrexon, will present at the Barclays Global Healthcare Conference on Wednesday, March 12, at 9:30 a.m. Eastern Time at the Loews Hotel in Miami, Florida. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy and... 
Printer Friendly Version
03/10/14Amneal and Intrexon Enter into Exclusive Channel Collaboration to Improve Active Pharmaceutical Ingredient Production
BRIDGEWATER, N.J. and GERMANTOWN, Md., March 10, 2014 /PRNewswire/ -- Amneal Pharmaceuticals LLC, the seventh largest generic drug manufacturer by volume in the U.S., and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the formation of an Exclusive Channel Collaboration (ECC) to develop an improved production process for a complex active pharmaceutical ingredient (API).  The companies will continue to explore other similar opportunities for collaboration in the f... 
Printer Friendly Version
03/07/14Intrexon Completes Acquisition of Medistem
GERMANTOWN, Md. and SAN DIEGO, March 7, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has completed the acquisition of San Diego-based Medistem, Inc. (OTCQB: MEDS), a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies. Upon integration of these plat... 
Printer Friendly Version
03/04/14Intrexon Strengthens Leadership to Further Advance Company's Environment Sector
Nir Nimrodi of Thermo Fisher Scientific's Life Technologies Division to join as Senior Vice President GERMANTOWN, Md., March 4, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Nir Nimrodi, currently Vice President and General Manager of Food Safety and Animal Health at Life Technologies, Inc., now part of Thermo Fisher Scientific, to head Intrexon's Environment Sector, reporting to Chairman and Chief Executive Officer ... 
Printer Friendly Version
02/03/14Intrexon to Present at the 2014 BIO CEO & Investor Conference
GERMANTOWN, Md., Feb. 3, 2014 /PRNewswire/ -- Intrexon Corporation, (NYSE: XON), a leader in synthetic biology, announced today that Krish Krishnan, Chief Operating Officer of Intrexon, will present at the BIO CEO & Investor Conference on Monday, Feb. 10, at 9:00 a.m. Eastern Standard Time at the Waldorf Astoria in New York. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy and th... 
Printer Friendly Version
01/13/14Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos Syndrome
Growing Pipeline of Protein Replacement Therapies for Rare Connective Tissue Disorders EXTON, Pa. and GERMANTOWN, Md., Jan. 13, 2014 /PRNewswire/ -- Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) to ... 
Printer Friendly Version
01/07/14Intrexon to Present at the 2014 J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 7, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 15, at 1:30 p.m. Pacific Standard Time at the Westin St. Francis in San Francisco. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Hea... 
Printer Friendly Version

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds |

Share Page

X
| E-mail Alerts E-mail Alerts | IR Contacts Contact US | Financial Tear Sheet Financial Tear Sheet